ARS Pharmaceuticals, (SPRY) announced the U.S. FDA has approved updating theneffy 1 mg or epinephrine nasal spray prescribing information to remove the age criteria so all children and adults who weigh 33 lbs. or more can utilize neffy for the emergency treatment of Type 1 allergic reactions, including anaphylaxis. The label update recommends patients carry neffy in the blister packaging or in the neffy carrying case.
Nicole Chase, Allergy/Immunology and Pediatrics, said: "Having a needle-free epinephrine treatment available for anyone who meets the weight criteria is an important step forward, in broadening access, lowering treatment hurdles, and supporting caregivers who are doing everything they can to protect their children."
At last close, ARS Pharma shares were trading at $8.56, up 8.35%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.